VCYT AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
VCYT Current Performance
-0.17%
Veracyte inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to VCYT
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
ADPT | Adaptive biotechnologies corp | 4 | 5 | 2 | 1 | 1 | |
TWST | Twist bioscience corp | 3 | 5 | 4 | 3 | 1 | |
NTLA | Intellia therapeutics inc | 4 | 3 | 2 | 3 | 1 | |
EXAS | Exact sciences corporation | 3 | 3 | 3 | 3 | 1 | |
TXG | 10x genomics inc | 1 | 3 | 4 | 3 | 1 |
- ADPT Adaptive biotechnologies corpValue 4Trend 5Swing Trading 2Whale Interest 1Dividend 1See more
VCYT Profile
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.